<DOC>
	<DOCNO>NCT01399619</DOCNO>
	<brief_summary>aim trial evaluate efficacy safety BI 201335 give 12 24 week combination PegIFN/RBV give 24-48 week , accord re-randomisation Early Treatment Success ( ETS ) patient 24 week stop PegIFN/RBV continue PegIFN/RBV week 48 . If ETS , PegIFN/RB 48 week , HCV treatment-naive relapsers patient coinfected HIV</brief_summary>
	<brief_title>Phase III Trial BI 201335 ( Faldaprevir ) Treatment Naive ( TN ) Relapser Hepatitis C Virus ( HCV ) -Human Immunodeficiency Virus ( HIV ) Coinfected Patients ( STARTverso 4 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion criterion : 1 . Chronic hepatitis C ( HCV ) genotype 1 infection 2 . Chronic Human Immunodeficiency Virus ( HIV ) 1 infection 3 . HCV treatment naive HCV treatment experience relapsers 4 . Age 18 70 year 5 . Antiretroviral treatment naive stable Highly Active Antiretroviral Therapy ( HAART ) 6 . Karnofsky score &gt; 70 7 . HCV viral load &gt; 1.000 IU/mL Exclusion criterion : 1 . HCV infection mixed genotype ( 1/2 , 1/3 , 1/4 ) 2 . Evidence acute chronic liver due chronic HCV infection 3 . Hepatitis B virus ( HBV ) infection presence HBsAg 4 . Active malignancy history malignancy within last 5 year 5 . Received concomitant systemic antiviral ( antiretroviral ) , hematopoietic growth factor immunomodulatory treatment 28 day prior enrolment . 6 . Decompensated liver disease , evidence ascites , hepatic encephalopathy , esophageal variceal bleeding , and/or laboratory value add &gt; /= 7 point accord tho ChildTurcottePugh classification 7 . Hemoglobin &lt; /=11g/dL woman &lt; /= 12 g/dL men 8 . Patients stable cardiac disease Hemoglobin &lt; 12g/dL 9 . Known hypersensitivity ingredient study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>